Skip to content
Open access

Clinical trial: The Effect on Intragastric pH and Pharmacokinetics of the PCAB Linaprazan Glurate in Healthy Subjects After Repeat‐Dose Administration for up to 14 Days

Oct 2026 · Alimentary Pharmacology and Therapeutics · Vol 64, pp. 1390 - 1401 · 0 citations · 17 references
Medicine

Abstract

Linaprazan glurate (LG), a potassium‐competitive acid blocker (PCAB), has shown up to 100% and 93% 4‐week healing rates in a Phase 2 study in patients with LA grade A/B and C/D erosive oesophagitis, respectively.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.